Odyssean LLC acquired a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 85,497 shares of the company’s stock, valued at approximately $2,636,000. Odyssean LLC owned 0.07% of Arcus Biosciences at the end of the most recent quarter.
Several other large investors have also made changes to their positions in RCUS. GAMMA Investing LLC increased its stake in shares of Arcus Biosciences by 10.0% in the second quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock worth $122,000 after acquiring an additional 359 shares during the period. Royal Bank of Canada lifted its position in Arcus Biosciences by 14.6% during the first quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock valued at $102,000 after purchasing an additional 607 shares during the period. Creative Planning lifted its position in Arcus Biosciences by 2.7% during the third quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after purchasing an additional 771 shares during the period. Hantz Financial Services Inc. boosted its holdings in Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after purchasing an additional 881 shares during the last quarter. Finally, New York State Teachers Retirement System boosted its holdings in Arcus Biosciences by 1.1% in the fourth quarter. New York State Teachers Retirement System now owns 92,431 shares of the company’s stock valued at $2,203,000 after purchasing an additional 1,000 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.
Arcus Biosciences Stock Performance
Shares of NYSE RCUS opened at $31.42 on Wednesday. The company has a market capitalization of $4.00 billion, a PE ratio of -8.06 and a beta of 0.80. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.82 and a current ratio of 3.82. The company’s fifty day moving average price is $28.78 and its 200 day moving average price is $24.91. Arcus Biosciences, Inc. has a 1 year low of $10.07 and a 1 year high of $31.74.
Analysts Set New Price Targets
Several brokerages have weighed in on RCUS. The Goldman Sachs Group reaffirmed a “buy” rating and set a $42.00 price target on shares of Arcus Biosciences in a research report on Friday, August 7th. Morgan Stanley set a $23.00 price objective on Arcus Biosciences in a report on Monday, August 10th. Wells Fargo & Company upped their target price on Arcus Biosciences from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 6th. Wall Street Zen lowered Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Lifesci Capital started coverage on Arcus Biosciences in a research report on Thursday, June 4th. They set an “outperform” rating and a $46.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.80.
Read Our Latest Stock Analysis on Arcus Biosciences
Insider Transactions at Arcus Biosciences
In related news, President Juan C. Jaen sold 20,067 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $28.62, for a total value of $574,317.54. Following the completion of the transaction, the president owned 822,240 shares of the company’s stock, valued at approximately $23,532,508.80. This represents a 2.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,827 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the transaction, the chief accounting officer owned 39,581 shares in the company, valued at $1,187,430. This represents a 6.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,389 shares of company stock worth $3,060,164 over the last 90 days. Insiders own 7.60% of the company’s stock.
Arcus Biosciences Profile
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.
The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.
Featured Articles
- Five stocks we like better than Arcus Biosciences
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
